towards improved death receptor targeted therapy for ... - TI Pharma

Chapter 2
and ERK pathways. Circulation 2003; 107(17):2250‐2256.
109. Li JH, Kirkiles‐Smith NC, McNiff JM, Pober JS. TRAIL induces apoptosis and inflammatory
gene expression in human endothelial cells. J Immunol 2003; 171(3):1526‐1533.
110. Secchiero P, Corallini F, di Iasio MG, Gonelli A, Barbarotto E, Zauli G. TRAIL counteracts the
proadhesive activity of inflammatory cytokines in endothelial cells by down‐modulating
CCL8 and CXCL10 chemokine expression and release. Blood 2005; 105(9):3413‐3419.
111. Wilson NS, Yang A, Yang B, Couto S, Stern H, Gogineni A et al. Proapoptotic activation of
death receptor 5 on tumor endothelial cells disrupts the vasculature and reduces tumor
growth. Cancer Cell 2012; 22(1):80‐90.
112. Secchiero P, Zerbinati C, Rimondi E, Corallini F, Milani D, Grill V et al. TRAIL promotes the
survival, migration and proliferation of vascular smooth muscle cells. Cell Mol Life Sci
2004; 61(15):1965‐1974.
113. Kavurma MM, Schoppet M, Bobryshev YV, Khachigian LM, Bennett MR. TRAIL stimulates
proliferation of vascular smooth muscle cells via activation of NF‐kappaB and induction of
insulin‐like growth factor‐1 receptor. J Biol Chem 2008; 283(12):7754‐7762.
114. Chan J, Prado‐Lourenco L, Khachigian LM, Bennett MR, Di Bartolo BA, Kavurma MM. TRAIL
promotes VSMC proliferation and neointima formation in a FGF‐2‐, Sp1 phosphorylation‐,
and NFkappaB‐dependent manner. Circ Res 2010; 106(6):1061‐1071.
115. Chou AH, Tsai HF, Lin LL, Hsieh SL, Hsu PI, Hsu PN. Enhanced proliferation and increased
IFN‐gamma production in T cells by signal transduced through TNF‐related apoptosis‐
inducing ligand. J Immunol 2001; 167(3):1347‐1352.
116. Robertson NM, Zangrilli JG, Steplewski A, Hastie A, Lindemeyer RG, Planeta MA et al.
Differential expression of TRAIL and TRAIL receptors in allergic asthmatics following
segmental antigen challenge: evidence for a role of TRAIL in eosinophil survival. J Immunol
2002; 169(10):5986‐5996.
117. Morel J, Audo R, Hahne M, Combe B. Tumor necrosis factor‐related apoptosis‐inducing
ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through
mitogen‐activated protein kinases and phosphatidylinositol 3‐kinase/Akt. J Biol Chem
2005; 280(16):15709‐15718.
118. Rimondi E, Secchiero P, Quaroni A, Zerbinati C, Capitani S, Zauli G. Involvement of
TRAIL/TRAIL‐receptors in human intestinal cell differentiation. J Cell Physiol 2006;
206(3):647‐654.
119. Wu NL, Lee TA, Tsai TL, Lin WW. TRAIL‐induced keratinocyte differentiation requires
caspase activation and p63 expression. J Invest Dermatol 2011; 131(4):874‐883.
120. Yen ML, Tsai HF, Wu YY, Hwa HL, Lee BH, Hsu PN. TNF‐related apoptosis‐inducing ligand
(TRAIL) induces osteoclast differentiation from monocyte/macrophage lineage precursor
cells. Mol Immunol 2008; 45(8):2205‐2213.
121. Kim JY, Lee JY, Kim DG, Koo GB, Yu JW, Kim YS. TRADD is critical for resistance to TRAIL‐
induced cell death through NF‐kappaB activation. FEBS Lett 2011; 585(14):2144‐2150.
122. Lluis JM, Nachbur U, Cook WD, Gentle IE, Moujalled D, Moulin M et al. TAK1 is required for
survival of mouse fibroblasts treated with TRAIL, and does so by NF‐kappaB dependent
induction of cFLIPL. PLoS One 2010; 5(1):e8620.
123. Cao X, Pobezinskaya YL, Morgan MJ, Liu ZG. The role of TRADD in TRAIL‐induced apoptosis
and signaling. FASEB J 2011; 25(4):1353‐1358.
124. Jurewicz A, Matysiak M, Andrzejak S, Selmaj K. TRAIL‐induced death of human adult
oligodendrocytes is mediated by JNK pathway. Glia 2006; 53(2):158‐166.
‐ 38 ‐